FDA Updates News 23 December 2025

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

New York, January 6, 2026, 15:27 (ET) — Regular session Nasdaq-listed Travere Therapeutics shares fell 5.3% to $36.09 in afternoon trading on Tuesday as investors looked toward next week’s U.S. FDA decision deadline on expanding its kidney drug Filspari (sparsentan)

6 January 2026

Biotech News·FDA Updates·Investment Analysis·Pharmaceutical Industry·Stock Market

Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus

NEW YORK, January 4, 2026, 13:49 ET — Market closed Dyne Therapeutics shares closed down 5.5% on Friday at $18.50, ending the first U.S. trading session of 2026 on a softer note. About 2.65 million shares changed hands. The pullback

4 January 2026

Biotech Stocks·Earnings Reports·FDA Updates·Investment Analysis·Market News

Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates

NEW YORK, January 1, 2026, 21:21 ET — Market closed With U.S. markets closed for New Year’s Day, shares of Arcutis Biotherapeutics Inc (ARQT) last closed up 3.42% at $29.04 in the final trading session of 2025. The stock ranged

2 January 2026

Biotech News·Earnings Reports·FDA Updates·Stock Market

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

NEW YORK, January 1, 2026, 10:45 ET — Market closed. Corcept Therapeutics Inc (CORT) shares last ended Wednesday down 50.4% at $34.80 after the company said U.S. regulators were not ready to approve its drug relacorilant for a form of

1 January 2026

Biotech News·FDA Updates·Investment Analysis·Pharmaceutical Industry·Stock Market

Disc Medicine (IRON) stock today: year-end rally keeps January FDA decision in focus

NEW YORK, January 1, 2026, 10:07 ET — Market closed Disc Medicine, Inc. shares rose 3.3% to $79.41 in the last U.S. trading session of 2025, before Wall Street shut on Thursday for the New Year’s Day holiday. Investors are

1 January 2026

Biotech News·FDA Updates·Healthcare Stocks·Investment Strategies·Stock Market

Ultragenyx stock today: RARE steadies premarket after setrusumab Phase 3 miss, FDA gene-therapy filing in focus

NEW YORK, December 31, 2025, 09:15 ET — Premarket Ultragenyx Pharmaceutical (RARE.O) shares edged down 0.2% to $22.74 in premarket trading on Wednesday, after finishing Tuesday up 15.5% at $22.78. The stock’s 52-week range is $18.41 to $46.50. StockAnalysis The

31 December 2025

Biotech·Clinical Trials·FDA Updates·Stock Market

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

NEW YORK, December 30, 2025, 15:25 ET — Regular session Scholar Rock Holding Corp (SRRK) slid 3.2% to $43.76 in afternoon trading on Tuesday after opening at $45.18. The stock traded between $45.95 and $43.74. The move matters because Scholar

30 December 2025

Biotech News·FDA Updates·Investment Analysis·Market Trends·Stock Market

Merck Stock (MRK) News and Forecasts: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Cidara Acquisition in Focus Ahead of the Next Market Session

As of 2:34 a.m. ET in New York on Saturday, December 27, 2025, U.S. stock markets are closed for the weekend.Merck & Co., Inc. (NYSE: MRK) was last quoted around $106.78, up about 0.33% versus its prior close, based on

27 December 2025

FDA Updates·Investment Analysis·Mergers & Acquisitions·Pharma News·Stock Market

FDA Frozen Shrimp Recall Over Cesium-137: Market 32 and Waterfront Bistro Products Pulled Across 17 States

Dec. 25, 2025 — If shrimp cocktail, shrimp scampi, or a quick freezer-to-pan seafood dinner is part of your holiday week, check your freezer before you cook. A new FDA-posted recall involves about 83,800 bags of frozen raw shrimp that

25 December 2025

FDA Updates

Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics, Inc. (NASDAQ: TVTX) is ending 2025 with a bang. In the holiday-shortened U.S. trading session on Wednesday, December 24, 2025, TVTX surged sharply—pushing to fresh highs as investors recalibrated around two big themes: accelerating commercial execution for FILSPARI

24 December 2025

Biotech News·FDA Updates·Financial Trends·Investment Analysis·Stock Market

Merck (MRK) Stock News and Forecasts for Dec. 23, 2025: TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Wall Street’s Latest Targets

Merck & Co., Inc. (NYSE: MRK) is closing in on year-end with a rare mix of policy-driven headlines, regulatory acceleration, and pipeline catalysts that are shaping investor expectations for 2026 and beyond. From a White House-backed drug-pricing framework that offers

23 December 2025

FDA Updates·Investment News·Market Analysis·Pharmaceuticals·Stock Market

GSK Stock News Today (Dec. 23, 2025): Buyback Update, Director Buying, US Drug-Pricing Deal, and FDA Wins — What Analysts Forecast Next

GSK plc stock is ending 2025 with a dense cluster of catalysts—some bullish, some complicated, and all very “big pharma in an election-year policy blender.” Early Tuesday (Dec. 23, 2025), GSK’s ADR (NYSE: GSK) traded around $48.59, essentially flat on

23 December 2025

Analyst Forecasts·FDA Updates·Investment Insights·Pharmaceutical Industry·Stock Market News

FDA Updates News 23 December 2025 - 6 January 2026